RGC Stock Analysis: Buy, Sell, or Hold?
RGC - Regencell Bioscience Holdings Limited Ordinary Shares
$11.08
0.57 (5.42%)
▲
5d:
-35.17%
30d:
-58.96%
90d:
-56.06%
WAIT
LOW Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Jun 02, 2026
0d
Get Alerted When RGC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RGC is down 35.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RGC is down 35.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RGC is currently trading at $11.08, which is considered oversold relative to its 30-day fair value range of $16.32 to $26.43.
Technical Outlook: Technically, RGC is in a downtrend. Immediate support is located at $10.15, while resistance sits at $21.91. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RGC is in a downtrend. Immediate support is located at $10.15, while resistance sits at $21.91. The stock is showing strong short-term momentum, up 5.4% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (18th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$16.32 -
$26.43
Company Quality Score
49/100
(HOLD)
Options IV Signal
18th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 18th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.4%)
- WARNING: Recommendation downgraded due to -35.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$16.32 -
$26.43
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$1.96
(17.7%)
Support & Resistance Levels
Support Level
$10.15
Resistance Level
$21.92
Current Trend
Downtrend
Technical data as of
Jun 23, 2026
Fundamental Context
Share & Embed Analysis
Last updated: June 23, 2026 5:40 PM ET
Data refreshes hourly during market hours. Next update: 6:40 PM
Data refreshes hourly during market hours. Next update: 6:40 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RGC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$194 | 60 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$105 | 64 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 67 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$125 | 58 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$665 | 57 HOLD |
